Gilead Sciences to buy Immunomedics in over $20 billion deal

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a transaction that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal has reported.

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced on Monday if not sooner, the Journal said, citing people familiar with the matter.

Discussions between Gilead and Immunomedics were initially centred around a partnership before shifting to a full-fledged takeover negotiation, the Journal added.

Shares of Immunomedics, which last month reported positive data from a late-stage confirmatory study for Trodelvy, have nearly doubled this year, giving the company a valuation of close to $10 billion.

READ MORE: Exorbitant price of Gilead's Covid-19 drug irks consumer groups

Expanding oncology portfolio

An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio.

It bought a 49.9 percent stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.

READ MORE: US FDA may announce emergency use of Gilead's coronavirus drug